depending on the top-line results of the dose escalation phase
UNIVERSAL REGISTRATION
DOCUMENT 2021
This Universal Registration Document was filed with the Autorité des marchés financiers, the French Financial Markets Authority, hereinafter the AMF, on 30 April 2021 as the competent authority under Regulation (EU) No 2017/1129, without prior approval in accordance with Article 9 of that Regulation.
The Universal Registration Document may be used for the purpose of offering financial securities to the public or for the admission of financial securities to trading in a regulated market if supplemented by a prospectus and, if applicable, a summary and all the amendments made to the Universal Registration Document. The resulting document package has been approved by the AMF in accordance with Regulation (EU) No 2017/1129.
Pursuant to Article 19 of Regulation (EU) No 2017/1129, the following information is included by reference in this Universal Registration Document:
- For the 2019 financial year, the ABIVAX Registration Document filed with the AMF on 25 May 2020 under number D.20-0483, contains the historical parent company financial statements, the Statutory Auditor's reports, the Management report, as well as key figures about ABIVAX; and
- For the 2018 financial year, the ABIVAX Registration Document filed with the AMF on 29 April 2019 under number D.19-
0437, contains the historical parent company financial statements, the Statutory Auditor's reports, the Management report, as well as key figures about ABIVAX;
Copies of this Universal Registration Document are available free of charge from the Company at 5 rue de la Baume, 75008 Paris, France, as well as electronically on the Company's website (www.ABIVAX.com) and on the AMF's website (www.amf-france.org).
CONTENTS
• | GENERAL REMARKS.................................................................................................................................. | 5 |
1. PERSONS RESPONSIBLE, INFORMATION FROM A THIRD PARTY, EXPERTS' REPORT AND APPROVAL OF THE
COMPETENT AUTHORITY ................................................................................................................................................... | 7 | ||
1.1 | Person(s) responsible for the Universal Registration Document............................................................... | 7 | |
1.2 | Statement by the Responsible Person ...................................................................................................... | 7 | |
1.3 | Name, address, qualifications and potential interests of persons involved as experts ............................. | 7 | |
1.4 | Statement about information from a third party...................................................................................... | 7 | |
1.5 | Declaration without prior approval by the competent authority.............................................................. | 7 | |
2. | STATUTORY AUDITORS............................................................................................................................................. | 8 | |
2.1 | Auditor..................................................................................................................................................... | 8 | |
2.2 | Statutory auditors who have resigned or been dismissed ........................................................................ | 8 | |
3. | RISK FACTORS ........................................................................................................................................................... | 9 | |
3.1 | Risks related to the Company's business ................................................................................................. | 10 | |
3.2 | The Company's financial and market risks............................................................................................... | 16 | |
3.3 | Regulatory and legal risks........................................................................................................................ | 20 | |
3.4 | Risks related to the Company's organisation........................................................................................... | 24 | |
4. INFORMATION ABOUT THE COMPANY.................................................................................................................. | 27 | ||
4.1 | Legal and commercial name of the Company .......................................................................................... | 27 | |
4.2 | Place, registration number and legal entity identifier of the Company.................................................... | 27 | |
4.3 | Date of incorporation and duration of the Company............................................................................... | 27 | |
4.4 | Registered office, legal form, laws governing its operations.................................................................... | 27 | |
5. | OVERVIEW OF ACTIVITIES ...................................................................................................................................... | 28 | |
5.1 | Main activities......................................................................................................................................... | 28 | |
5.2 | Main markets .......................................................................................................................................... | 51 | |
5.3 | Significant events in the growth of the Company's business since 2018 .................................................. | 51 | |
5.4 | Strategy and objectives ........................................................................................................................... | 53 | |
5.5 | Patents, licences, trademarks, names and domain names....................................................................... | 54 | |
5.6 | The competitive environment ................................................................................................................. | 75 | |
5.7 | Investments ............................................................................................................................................ | 76 | |
6. | ORGANISATIONAL STRUCTURE .............................................................................................................................. | 77 | |
6.1 | Organisation of the Company.................................................................................................................. | 77 | |
6.2 | List of subsidiaries, branches and secondary establishments .................................................................. | 77 | |
7. REVIEW OF THE FINANCIAL POSITION AND OF THE RESULTS ............................................................................... | 78 | ||
7.1 | Financial position .................................................................................................................................... | 78 | |
7.2 | Operating income.................................................................................................................................... | 86 | |
8. | CASH AND CAPITAL................................................................................................................................................. | 88 | |
8.1 | Information on the capital of the Company............................................................................................. | 88 | |
8.2 | Sources and uses of cash of the Company ............................................................................................... | 90 | |
8.3 | Financing needs and financing structure ................................................................................................. | 91 |
2 | UNIVERSAL REGISTRATION DOCUMENT 2021
8.4 Restrictions on the use of capital which have materially affected or may materially affect the Company's
operations directly or indirectly ............................................................................................................................ | 94 | |
8.5 | Expected sources of funding.................................................................................................................... | 94 |
9. REGULATORY ENVIRONMENT................................................................................................................................ | 97 |
9.1 Description of the regulatory environment and any measures of an administrative, economic, budgetary,
monetary and political nature............................................................................................................................... | 97 | |
10. INFORMATION ON TRENDS.................................................................................................................................. | 107 | |
10.1 | Main trends since the beginning of the current financial year ............................................................... | 107 |
10.2 Trends, uncertainties, constraints, commitments or events likely to have a material impact on the
Company's outlook ............................................................................................................................................. | 107 | |
11. | PROFIT FORECASTS OR ESTIMATES...................................................................................................................... | 109 |
12. | ADMINISTRATIVE, MANAGEMENT AND SUPERVISING BODIES AND GENERAL MANAGEMENT....................... | 110 |
12.1 | Executives, directors and non-voting directors...................................................................................... | 110 |
12.2 | Conflicts of interest of administrative and executive bodies ................................................................. | 117 |
12.3 Procedure for the evaluation of agreements relating to current operations and concluded under normal
conditions ........................................................................................................................................................... | 118 | |
13. COMPENSATION AND BENEFITS .......................................................................................................................... | 119 | |
13.1 | Executive compensation and benefits in kind........................................................................................ | 119 |
13.2 Sums provisioned by the Company for the payment of pensions, retirement benefits and other benefits
to corporate officers ........................................................................................................................................... | 128 | |
14. FUNCTIONING OF ADMINISTRATIVE AND MANAGEMENT BODIES .................................................................... | 129 | |
14.1 | Expiry dates of terms of office............................................................................................................... | 129 |
14.2 | Information on the agreements between the executives and/or the directors and the Company......... | 129 |
14.3 | Information on the Audit Committee, the Compensation Committee and the Scientific Committee .... | 129 |
14.4 | Statement relating to corporate governance......................................................................................... | 131 |
14.5 | Potential significant impacts on corporate governance ......................................................................... | 132 |
14.6 | Internal control of accounting and financial information ...................................................................... | 132 |
15. | EMPLOYEES........................................................................................................................................................... | 133 |
15.1 | Human resources .................................................................................................................................. | 133 |
15.2 | Shareholdings and stock options of corporate officers .......................................................................... | 136 |
15.3 | Agreement providing for shareholdings of employees .......................................................................... | 136 |
16. | MAJOR SHAREHOLDERS ....................................................................................................................................... | 137 |
16.1 | Breakdown of capital and voting rights ................................................................................................. | 137 |
16.2 | Major shareholders' voting rights.......................................................................................................... | 139 |
16.3 | Direct or indirect control of the Company ............................................................................................. | 139 |
16.4 | Agreements that, when implemented, could result in a change of control............................................ | 140 |
16.5 | Changes in share price........................................................................................................................... | 140 |
17. | RELATED-PARTYTRANSACTIONS ......................................................................................................................... | 142 |
17.1 | Details of related-party transactions ..................................................................................................... | 142 |
18. FINANCIAL INFORMATION ABOUT THE ISSUER'S ASSETS AND LIABILITIES, FINANCIAL POSITION AND RESULTS
145
18.1 | Historical financial information ............................................................................................................. | 145 |
18.2 | Interim and other financial information ................................................................................................ | 180 |
3 | UNIVERSAL REGISTRATION DOCUMENT 2021
18.3 | Audit of historical annual financial information .................................................................................... | 181 |
18.4 | Pro forma financial information ............................................................................................................ | 181 |
18.5 | Dividend policy...................................................................................................................................... | 181 |
18.6 | Administrative, legal and arbitration proceedings................................................................................. | 182 |
18.7 | Significant changes in the financial or trading position.......................................................................... | 182 |
19. | ADDITIONAL INFORMATION ................................................................................................................................ | 183 |
19.1 | Share capital.......................................................................................................................................... | 183 |
19.2 | Charter and Articles of Association........................................................................................................ | 201 |
20. | MAJOR CONTRACTS.............................................................................................................................................. | 212 |
20.1 | Collaboration and research and development contracts ....................................................................... | 212 |
20.2 Main contracts for the provision of services and mandates with clinical research organisations (CRO) and
centralised laboratories ...................................................................................................................................... | 212 | |
20.3 | Intellectual property rights assignment contract................................................................................... | 213 |
20.4 | Bpifrance aid contracts (grants and/or repayable advances) ................................................................. | 213 |
20.5 | Other financial agreements ................................................................................................................... | 217 |
21. | PUBLICLY AVAILABLE DOCUMENTS ..................................................................................................................... | 218 |
22. | MANAGEMENT REPORT CROSS-REFERENCETABLE ............................................................................................ | 219 |
22.1 | Cross-reference table with the annual financial report.......................................................................... | 219 |
22.2 | Cross-reference table with the management report.............................................................................. | 219 |
22.3 | Cross-reference table with the report on corporate governance ........................................................... | 220 |
4 | UNIVERSAL REGISTRATION DOCUMENT 2021
Attachments
- Original document
- Permalink
Disclaimer
Abivax SA published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2021 13:39:03 UTC.